ESTIMATED ANNUALIZED BURDEN HOURS

| Form | Respondents | Number of respondents | Number of responses per respondent | Average burden per response (in hrs.) | Total burden (in hours) |
|---|---|---|---|---|---|
| Web-based survey on CVH Toolkit .. | State Heart Disease and Stroke Programs. | 51 | 1 | 0.5 | 25.5 |

Dated: January 25, 2007.

**Joan F. Karr,**

*Acting Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. E7–1489 Filed 1–30–07; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Cooperative Agreement for Enhancing Public Health Practice Related to Birth Defects and Developmental Disabilities, Request for Application (RFA) DD07–002 and Cooperative Agreement for a National Research and Training Organization for People With Developmental and Other Disabilities, RFA DD07–003

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned SEP:

*Time and Date:* 1 p.m.–4 p.m., March 19, 2007 (Closed).

*Place:* Teleconference.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

*Matters to Be Discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to RFA DD07–002, ''Cooperative Agreement for Enhancing Public Health Practice Related to Birth Defects and Developmental Disabilities,'' and RFA DD07–003, ''Cooperative Agreement for a National Research and Training Organization for People with Developmental and other Disabilities.''

*Contact Person for More Information:* Juliana Cyril, PhD, Associate Director for Policy and Peer Review, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Mailstop D72, Atlanta, GA 30333, Telephone 404.639.4639.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E7–1501 Filed 1–30–07; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect (NTFFASFAE): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned Federal advisory committee.

*Times and Dates:* 8:30 a.m.–4:30 p.m., February 28, 2007. 8:30 a.m.–1 p.m., March 1, 2007.

*Place:* SpringHill Suites Atlanta Buckhead, 3459 Buckhead Loop, NE., Atlanta, Georgia 30326, telephone 404/844–4800, fax 404/844–4801.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 80 people.

*Purpose:* The Secretary is authorized by the Public Health Service Act, Section 399G, (42 U.S.C. 280f, as added by Pub. L. 105–392) to establish a National Task Force on Fetal Alcohol Syndrome and Fetal Alcohol Effect to: (1) foster coordination among all governmental agencies, academic bodies and community groups that conduct or support Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effect (FAE) research, programs and surveillance; and (2) to otherwise meet the general needs of populations actually or potentially impacted by FAS and FAE.

*Matters to Be Discussed:* Agenda items include: Presentation of draft report on evidence-based fetal alcohol spectrum disorders (FASD) community-based prevention strategies with deliberations by the Task Force; presentation on U.S. Preventive Services Task Force report on alcohol use screening and behavioral counseling interventions; report on work of Post-exposure working group regarding recommendations for future directions in FASD policy and research; updates from the Interagency Coordinating Committee on FAS, the CDC and other Federal agencies, and liaison representatives; and scheduling of the next meeting.

Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* Mary Kate Weber, M.P.H., Designated Federal Official, National Center on Birth Defects and Developmental Disabilities, CDC, 1600 Clifton Road, NE., (E–86), Atlanta, Georgia 30333, telephone 404/498–3926, fax 404/498–3550.

The Acting Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

**Elaine L. Baker,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E7–1493 Filed 1–30–07; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Advisory Committee on Immunization Practices: Meeting

*Correction:* This notice was published in the **Federal Register** on December 8, 2006, Volume 71, Number 236, page 71175–71176. The matters to be discussed have changed.

*Matters To Be Discussed:* The agenda will include discussions on influenza vaccine; immunization safety; update on use of rotavirus vaccine; update on use of HPV vaccine; update on use of herpes zoster (shingles) vaccine; vaccine supply; Japanese encephalitis and other flavivirus vaccines (e.g., yellow fever vaccine); diphtheria, tetanus, pertussis, polio, Haemophilus B [Hib] combination vaccine (Pentacel®); evidence-based recommendations; and agency updates. Vaccine for Children votes will be on hepatitis A post exposure prophylaxis, influenza and Pentacel. Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* Demetria Gardner, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, NE., (E–05), Atlanta, Georgia 30333, telephone 404/639–8836, fax 404/639–6258.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

**Elaine L. Baker,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E7–1490 Filed 1–30–07; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 71 FR 69211, dated November 30, 2006) is amended to reflect the establishment of the Extramural Research Program Office within the National Center for Injury Prevention and Control, coordinating Center for Environmental Health and Injury Prevention.

Section C–B, Organization and Functions, is hereby amended as follows: After the functional statement for the *Office of Communication Resources (CTC14), Office of the Director (CTC1), National Center for Injury Prevention and Control (CTC),* insert the following:

*Extramural Research Program Office (CTC16).* The Extramural Research Program Office (ERPO) plans, develops, coordinates, and evaluates extramural research activities in cooperation with centers, divisions, and offices within the Coordinating Center for Environmental Health and Injury Prevention. In carrying out its mission, the ERPO: (1) Directs the Extramural research program by planning, coordinating, developing, implementing, monitoring, and evaluating extramural research that is designed to address center priorities; (2) participates with divisions and offices within the center to establish research priorities for the center; (3) provides scientific leadership in the areas of extramural research supported by the center; (4) promotes and prepares initiatives to stimulate extramural research in relevant priority areas; (5) coordinates and conducts in-depth external peer review and secondary program relevance review of extramural research applications by use of consultant expert panels; (6) makes recommendations to the center director on award selections and staff members serve as the program officials in conjunction with CDC grants management and policy officials to implement and monitor the scientific, technical, and administrative aspects of awards; (7) facilitates scientific collaborations between external and internal investigators; (8) disseminates and evaluates extramural research progress, findings, and impact; and (9) assists the Office of Chief Science Officer, CDC, in developing extramural research policies and oversees the implementation of those policies within the center.

Dated: January 9, 2007.

**William H. Gimson,**

*Chief Operating Officer, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 07–417 Filed 1–30–07; 8:45 am]

**BILLING CODE 4160–18–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2006N–0136]**

### Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Interstate Shellfish Dealers Certificate

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Interstate Shellfish Dealers Certificate'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

**FOR FURTHER INFORMATION CONTACT:** Jonna Capezzuto, Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of October 13, 2006 (71 FR 60545), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0021. The approval expires on January 31, 2010. A copy of the supporting statement for this information collection is available on the Internet at *http://www.fda.gov/ohrms/dockets*.

Dated: January 25, 2007.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. E7–1549 Filed 1–30–07; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[FDA 225–07–4300]**

### Memorandum of Understanding Between the United States Food and Drug Administration and the Veterans Health Administration

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the Veterans Health Administration. The purpose of this MOU is to enhance knowledge and efficiency by providing for the sharing of information and expertise related to the review and use of FDA-regulated drugs, biologics, and medical devices between the two agencies. The goals of the collaboration are to explore ways to: Further enhance information sharing efforts through more efficient and robust interagency activities; promote efficient utilization of tools and expertise for product risk identification, validation, and analysis; and build infrastructure and processes that meet the common needs for evaluating the safety, efficacy, and utilization of drugs, biologics, and medical devices.

**DATES:** The agreement became effective January 23, 2007.

**FOR FURTHER INFORMATION CONTACT:** Jeffrey Shuren, Office of Policy (HF–11), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3360.